Aclaris Therapeutics, Inc. (ACRS)
| Market Cap | 559.49M +101.8% |
| Revenue (ttm) | 6.40M -59.3% |
| Net Income | -79.63M |
| EPS | -0.59 |
| Shares Out | 154.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,331,431 |
| Open | 3.710 |
| Previous Close | 3.680 |
| Day's Range | 3.450 - 3.720 |
| 52-Week Range | 2.100 - 6.600 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 10.36 (+186.98%) |
| Earnings Date | Nov 5, 2026 |
About ACRS
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational... [Read more]
Financial Performance
In 2025, Aclaris Therapeutics's revenue was $7.83 million, a decrease of -58.19% compared to the previous year's $18.72 million. Losses were -$64.92 million, -50.84% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price target is $10.36, which is an increase of 186.98% from the latest price.
News
Aclaris Therapeutics reports Q3 EPS (12c), consensus (16c)
Reports Q3 revenue $1.48M, consensus $1.23M. Believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the first half of 2029, without giving...
Aclaris Therapeutics Earnings release: Q3 2026
Aclaris Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Aclaris Therapeutics Quarterly report: Q3 2026
Aclaris Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI...
Aclaris Therapeutics price target raised to $13 from $10 at Canaccord
Canaccord raised the firm’s price target on Aclaris Therapeutics (ACRS) to $13 from $10 and keeps a Buy rating on the shares. The firm said Aclaris reported positive data from…
Aclaris Therapeutics price target lowered to $9 from $10 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $9 from $10 and keeps a Buy rating on the shares following ATI-052’s POC data in atopic derm/asthma and…
Aclaris Therapeutics Transcript: Study result
ATI-052 showed proof-of-concept activity in severe AD and asthma, with early, durable AD responses, broad biomarker effects and rapid asthma improvements. Development is set to prioritize a dose-ranging Phase II-B/III program in EoE.
Aclaris Therapeutics Slides: Study result
Aclaris Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 27, 2026.
Aclaris Therapeutics Press release: Study result
Aclaris Therapeutics issued a press release on October 27, 2026, disclosing material business information to investors.
Aclaris Therapeutics prices 7.79M shares at $3.50 in public offering
Aclaris Therapeutics (ACRS) announced the pricing of an underwritten offering of 7,785,714 shares of its common stock at a price of $3.50 per share and, in lieu of shares of…
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...
Aclaris Therapeutics’ ATI-052 shows efficacy in atopic dermatitis, asthma trial
Aclaris Therapeutics (ACRS) announced positive primary analysis results from the Phase 1b proof-of-concept trials of its anti-TSLP/IL-4R alpha bispecific antibody ATI-052 in atopic dermatitis and asth...
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis
Aclaris Therapeutics management to meet virtually with Piper Sandler
Virtual Meeting to be held on October 6 hosted by Piper Sandler.
Aclaris Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Upcoming data releases in asthma and atopic dermatitis, new studies in lichen planus, and next-gen ITK inhibitors highlight a robust pipeline. Phase II-B trials are set for Q4, with funding secured through 2028. Lichen planus and bispecific programs are key value drivers.
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat...
Canaccord starts Aclaris with Buy on ‘sizeable’ U.S. opportunities
Canaccord analyst Edward Nash initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $10 price target The firm views Aclaris as a “catalyst-rich” immunology and inflammatory company n...
Aclaris Therapeutics initiated with a Buy at Canaccord
Canaccord analyst Edward Nash initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $10 price target
Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib
Aclaris Therapeutics (ACRS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation for modzatinib for moderate to severe lichen planus including oral erosive LP, cutan...
Aclaris Therapeutics files automatic mixed securities shelf
17:09 EDT Aclaris Therapeutics (ACRS) files automatic mixed securities shelf
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...
Aclaris Therapeutics reports Q2 EPS (15c), consensus (16c)
Reports Q2 revenue $1.6M, consensus $1.38M. As of June 30, Aclaris had cash, cash equivalents and marketable securities of $170.6M vs. $151.4M as of December 31, 2025. The company believes…
Aclaris Therapeutics Earnings release: Q2 2026
Aclaris Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Aclaris Therapeutics Quarterly report: Q2 2026
Aclaris Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line Res...